At close: December 30 at 5:30:19 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
47,271.00
47,271.00
-29,843.00
-37,359.00
-43,510.00
Investing Cash Flow
-18,044.00
-18,044.00
-3,932.00
69.00
1,563.00
Financing Cash Flow
-171.00
-171.00
13,993.00
46,022.00
23,150.00
End Cash Position
30,370.00
30,370.00
1,353.00
21,208.00
12,411.00
Capital Expenditure
-23,743.00
-23,743.00
-3,956.00
-15.00
-34.00
Issuance of Capital Stock
18,820.00
18,820.00
511.00
20,353.00
901.00
Issuance of Debt
7,500.00
7,500.00
33,000.00
35,792.00
24,559.00
Repayment of Debt
-25,475.00
-25,475.00
-18,446.00
-3,500.00
--
Repurchase of Capital Stock
--
--
--
-56.00
-922.00
Free Cash Flow
23,528.00
23,528.00
-33,799.00
-37,374.00
-43,544.00
12/31/2020 - 11/3/2006
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IDIA.SW Idorsia Ltd
0.8220
+1.80%
NWRN.SW Newron Pharmaceuticals S.p.A.
8.95
+1.47%
RLF.SW Relief Therapeutics Holding SA
4.2100
-5.39%
EVE.SW Evolva Holding SA
0.9000
+5.88%
BSLN.SW Basilea Pharmaceutica AG
41.35
-1.66%
ADXN.SW Addex Therapeutics Ltd
0.0572
+4.00%
CPRX Catalyst Pharmaceuticals, Inc.
21.52
+3.11%
MOLN.SW Molecular Partners AG
4.0600
-8.56%
FARN.L Faron Pharmaceuticals Oy
210.00
+2.44%
XLS.SW Xlife Sciences AG
25.40
+2.42%